Black+Decker vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Stanley Black & Decker-owned consumer power tool and appliance brand; 20V MAX cordless platform for DIY homeowners competing with Ryobi and Hart for mass retail tool market.
About
Black+Decker is a consumer power tool and home appliance brand producing a broad range of products including cordless drills, circular saws, sanders, and oscillating tools alongside kitchen appliances (coffee makers, toasters, hand mixers) and outdoor equipment — positioned as the accessible, value-oriented option for DIY homeowners who want reliable performance without professional-grade pricing. Black+Decker is owned by Stanley Black & Decker (NYSE: SWK), the global tool and storage company that also owns the flagship Stanley and DeWalt brands, with Black+Decker serving the consumer (home) market while DeWalt targets the professional trades market.\n\nBlack+Decker's product strategy centers on the entry-to-mid-level homeowner who needs a cordless drill for occasional home projects, not a contractor running tools all day. The brand's 20V MAX lithium-ion platform (shared battery ecosystem across drills, saws, and other tools) provides value to homeowners investing in multiple tools over time. The kitchen appliance line (under the Black+Decker brand) ranges from basic toasters to space-saving air fryers, competing in the mass-market kitchen appliance segment at Target, Walmart, and Home Depot.\n\nIn 2025, Black+Decker competes with Ryobi (TTI), Craftsman (Stanley Black & Decker), Hart (Walmart's private label tool brand), and Milwaukee (entry-level products) for the consumer power tool market. Stanley Black & Decker faced significant financial challenges in 2022-2023 from inventory excess and margin compression, leading to restructuring that rationalized the brand portfolio. Black+Decker's 2025 strategy within Stanley Black & Decker focuses on maintaining mass retail distribution (Home Depot, Walmart, Amazon), growing the 20V MAX battery ecosystem, and defending share against Walmart's Hart brand which competes directly on value pricing.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.